The obesity therapeutics landscape is undergoing a rapid transformation—from being viewed primarily as a public health burden to becoming a high-growth, innovation-driven market segment. Global investments, rising disease awareness, and a new wave of highly efficacious drugs have redefined both the clinical and commercial outlook for obesity care. In 2024, the market reached a key inflection point, with global spend on anti-obesity medications (AOMs) surpassing $30 billion—more than a tenfold increase since 2020. This growth has been driven by the commercial success and widespread adoption of GLP-1 and dual agonists like semaglutide and tirzepatide, along with significant off-label usage from their type 2 diabetes portfolios.
‘Global Obesity Report 2025’ offers a detailed overview of the rapidly evolving global obesity therapeutics market, organized around three core themes: market dynamics, regulatory developments, and research innovation. It captures the current landscape of obesity by examining the global disease burden, healthcare spending trends, the top-selling anti-obesity drugs of 2024, and recent strategic activities, including mergers, acquisitions, and mission-driven collaborations. The analysis underscores how breakthrough therapies are redefining industry benchmarks and attracting heightened investor interest. The report also delves into the drug approval and launch environment, providing insights into recent clearances for both novel and generic therapies—categorized by treatment type, regulatory agency (e.g., US FDA, EMA), and manufacturer. Additionally, it explores key R&D trends, highlighting clinical trial activity across phases, leading players in obesity-focused development, and the rise of next-generation solutions such as breakthrough therapies, precision medicine, and behavioral interventions. Collectively, these chapters chart the progression of obesity therapeutics from scientific discovery to large-scale commercial impact.
